Physician profile
Neida Jimenez
NPI 1295741072
$683.60
in general payments reported to CMS, 2019-2025
17 companies · $66.20 in 2025
The $66.20 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $327 · 2022: $170 · 2023: $82.45 · 2024: $37.48 · 2025: $66.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $186.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $194.81 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $95.97 | 2021-2023 | Jardiance |
| Novo Nordisk INC | $86.57 | 2021-2022 | |
| Amgen INC. | $55.73 | 2021-2022 | |
| Mylan Specialty L.P. | $31.26 | 2021 | |
| Amarin Pharma, INC. | $28.57 | 2021 | |
| Paratek Pharmaceuticals, INC. | $28.40 | 2021-2023 | Nuzyra |
| Esperion Therapeutics, INC. | $27.28 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.91 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.36 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.23 | 2023 | Spravato |
| Astrazeneca Pharmaceuticals LP | $14.50 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.41 | 2021 | |
| Lupin INC. | $13.64 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.63 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13.59 | 2022 | |
| Glaxosmithkline, LLC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neida Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.